Published June 2018 | Version v1
Journal article

Combined model-based and patient-specific dosimetry for 18F-DCFPyL, a PSMA-targeted PET agent

  • 1. Johns Hopkins University, The Russell H. Morgan Department of Radiology and Radiological Science, School of Medicine, Baltimore, MD (United States)
  • 2. University of Wisconsin, Department of Radiology, School of Medicine and Public Health, Baltimore, MD (United States)
  • 3. Johns Hopkins Medical Institutions, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD (United States)
  • 4. Johns Hopkins University, Department of Radiation Oncology, School of Medicine, Baltimore, MD (United States)

Description

Prostate-specific membrane antigen (PSMA), a type-II integral membrane protein highly expressed in prostate cancer, has been extensively used as a target for imaging and therapy. Among the available PET radiotracers, the low molecular weight agents that bind to PSMA are proving particularly effective. We present the dosimetry results for 18F-DCFPyL in nine patients with metastatic prostate cancer. Nine patients were imaged using sequential PET/CT scans at approximately 1, 12, 35 and 70 min, and a final PET/CT scan at approximately 120 min after intravenous administration of 321 ± 8 MBq (8.7 ± 0.2 mCi) of18F-DCFPyL. Time-integrated-activity coefficients were calculated and used as input in OLINDA/EXM software to obtain dose estimates for the majority of the major organs. The absorbed doses (AD) to the eye lens and lacrimal glands were calculated using Monte-Carlo models based on idealized anatomy combined with patient-specific volumes and activity from the PET/CT scans. Monte-Carlo based models were also developed for calculation of the dose to two major salivary glands (parotid and submandibular) using CT-based patient-specific gland volumes. The highest calculated mean AD per unit administered activity of 18F was found in the lacrimal glands, followed by the submandibular glands, kidneys, urinary bladder wall, and parotid glands. The S-values for the lacrimal glands to the eye lens (0.42 mGy/MBq h), the tear film to the eye lens (1.78 mGy/MBq h) and the lacrimal gland self-dose (574.10 mGy/MBq h) were calculated. Average S-values for the salivary glands were 3.58 mGy/MBq h for the parotid self-dose and 6.78 mGy/MBq h for the submandibular self-dose. The resultant mean effective dose of 18F-DCFPyL was 0.017 ± 0.002 mSv/MBq. 18F-DCFPyL dosimetry in nine patients was obtained using novel models for the lacrimal and salivary glands, two organs with potentially dose-limiting uptake for therapy and diagnosis which lacked pre-existing models. (orig.)

Availability note (English)

Available from: http://dx.doi.org/10.1007/s00259-018-3939-x

Additional details

Identifiers

Publishing Information

Journal Title
European Journal of Nuclear Medicine and Molecular Imaging
Journal Volume
45
Journal Issue
6
Journal Page Range
p. 989-998
ISSN
1619-7070
CODEN
EJNMA6